NVP BEP 800
Alternative Names: BEP-800; NVP BEP800; VER-82576Latest Information Update: 28 Dec 2023
At a glance
- Originator Cancer Research Technology; The Institute of Cancer Research; Vernalis
- Developer Centre Hospitalier Universitaire Dijon; Novartis; Vernalis
- Class Amides; Antineoplastics; Chlorobenzenes; Pyrimidines; Pyrrolidines; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in France (IV, Injection)
- 28 Jan 2022 No recent reports of development identified for preclinical development in Cancer in Europe (PO)
- 25 Jun 2020 Chemical structure information added